New screening approach identified potential drug combos for difficult-to-treat melanomas
A novel approach to identifying potential anticancer drug combinations revealed that pairing cholesterol-reducing drugs called statins with cyclin-dependent kinase inhibitors might provide an effective approach to treating intractable melanomas driven by mutations in the NRAS and KRAS gene.
David F. Stern, Ph.D., professor of pathology at Yale University School of Medicine in New Haven, Conn., and colleagues reported these data in Cancer Discovery, a journal of the American Association for Cancer Research.
"The identification of gene mutations that drive specific subsets of cancers has had a major beneficial impact on treatments for these patients. But, such mutations can only be identified for some cancers. Some patients who have a specific cancer-driving genetic mutation never respond to the matching drug, while nearly all those who initially respond eventually become resistant to the effects of the drug and their cancers relapse," said Stern.
For this reason, Stern and colleagues reasoned that using drug combinations may be necessary to address the problem of drug resistance and enable effective treatment of cancers driven by signaling molecules that currently cannot be targeted, such as RAS.
They developed an in vitro, high-throughput screen to test the effectiveness of anticancer drugs, alone and in pairs, against three types of melanoma cell lines: those driven by mutations in the RAS gene (representing approximately 20 percent of human melanomas), those driven by mutations in the BRAF gene (40 to 50 percent of melanomas) and those without mutations in either the RAS or BRAF genes.
Through analysis of 150 drugs as single agents, Stern and colleagues narrowed their pool to 40 drugs for combination testing. Melanoma cell lines driven by BRAF and RAS were sensitive to different combinations of drugs. Some combinations that killed BRAF-driven melanoma cell lines were also effective against BRAF-driven melanoma cell lines resistant to a single agent used to treat patients with melanoma tumors characterized by BRAF gene mutations, and these combinations may prove to be helpful in preventing or managing resistance to these agents.
"Perhaps the most interesting observation was that several drug combinations that included a statin, a drug class used clinically to lower cholesterol, killed RAS-driven melanoma cell lines, given the lack of success in treating such cancers," said Stern.
One statin combination that showed efficacy in vitro, simvastatin plus flavopiridol, an inhibitor of proteins called cyclin-dependent kinases that activate cell division, also worked in vivo substantially reducing the growth of a RAS-driven human melanoma cell line transplanted into mice.
"These agents may be extremely useful as partner agents in combination therapy. Since multiple cyclin-dependent kinase inhibitors are already in human clinical trials, there may be a short path to testing the combination of a statin plus a cyclin-dependent kinase inhibitor in patients with RAS-driven melanoma," said Stern. "There is a great need for drugs to treat cancers driven by RAS. RAS proteins are inappropriately active in up to a third of all human cancers, including melanoma and lung and pancreatic cancers."
"This brings up the important point that our high-throughput screening approach is applicable to other types of cancer, including lung and pancreatic cancer," he added. "A major challenge is in picking the appropriate agents for combination screening, since with multiple doses per agent, the scale of a screen needed for all combinations grows rapidly. This requires careful evaluation of single agents, and analytical methods for choosing the best candidates for follow-up in combinations. For our work, the relatively small number of genetic subtypes was very important, so this system provides a great starting point for investigation of carcinomas (lung, pancreatic cancer, breast cancer), which are genetically more complex."
Journal reference: Cancer Discovery
Provided by American Association for Cancer Research
- Discovery in cell signaling could help fight against melanoma May 10, 2012 | not rated yet | 0
- Study uncovers mechanism by which melanoma drug accelerates secondary skin cancers Jan 18, 2012 | not rated yet | 0
- Second mutation in BRAF-mutated melanoma doesn't contribute to resistance Apr 01, 2012 | not rated yet | 0
- Drug combination against NRAS-mutant melanoma discovered Sep 17, 2012 | not rated yet | 0
- Uncommon BRAF mutation in melanoma sensitive to MEK inhibitor drug therapy Jul 16, 2012 | not rated yet | 0
- Motion perception revisited: High Phi effect challenges established motion perception assumptions Apr 23, 2013 | 3 / 5 (2) | 2
- Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update) Apr 02, 2013 | 4.5 / 5 (11) | 5
- The visual system as economist: Neural resource allocation in visual adaptation Mar 30, 2013 | 5 / 5 (2) | 9
- Separate lives: Neuronal and organismal lifespans decoupled Mar 27, 2013 | 4.9 / 5 (8) | 0
- Sizing things up: The evolutionary neurobiology of scale invariance Feb 28, 2013 | 4.8 / 5 (10) | 14
Pressure-volume curve: Elastic Recoil Pressure don't make sense
May 18, 2013 From pressure-volume curve of the lung and chest wall (attached photo), I don't understand why would the elastic recoil pressure of the lung is...
If you became brain-dead, would you want them to pull the plug?
May 17, 2013 I'd want the rest of me to stay alive. Sure it's a lousy way to live but it beats being all-the-way dead. Maybe if I make it 20 years they'll...
MRI bill question
May 15, 2013 Dear PFers, The hospital gave us a $12k bill for one MRI (head with contrast). The people I talked to at the hospital tell me that they do not...
Ratio of Hydrogen of Oxygen in Dessicated Animal Protein
May 13, 2013 As an experiment, for the past few months I've been consuming at least one portion of Jell-O or unflavored Knox gelatin per day. I'm 64, in very...
Alcohol and acetaminophen
May 13, 2013 Edit: sorry for the typo in the title , can't edit I looked around on google quite a bit and it's very hard to find precise information on the...
Marie Curie's leukemia
May 13, 2013 Does anyone know what might be the cause of Marie Curie's cancer
- More from Physics Forums - Medical Sciences
More news stories
The use of a smartphone application significantly improves patients' preparation for a colonoscopy, according to new research presented today at Digestive Disease Week (DDW). The preparation process, which begins days in ...
Cancer 19 hours ago | not rated yet | 0
Research presented at Digestive Disease Week (DDW) explores new methods for managing digestive health through diet and lifestyle.
Cancer 19 hours ago | not rated yet | 1
A ground-breaking advance in colonoscopy technology signals the future of colorectal care, according to research presented today at Digestive Disease Week(DDW). Additional research focuses on optimizing the minimal withdrawal ...
Cancer May 18, 2013 | 5 / 5 (2) | 0
(HealthDay)—Concurrent use of two immune checkpoint antibodies—ipilimumab and nivolumab—may be effective for the treatment of advanced melanoma, according to a proof-of-principal study presented in ...
Cancer May 17, 2013 | not rated yet | 0
(HealthDay)—The risks of metastasis and death associated with cutaneous squamous cell carcinoma (CSCC) are low, but significant, and risk factors for poor outcome include tumor diameter, invasion beyond ...
Cancer May 17, 2013 | not rated yet | 0 |
Researchers at the University of Wisconsin have identified a potential new risk factor for obstructive sleep apnea: asthma. Using data from the National Institutes of Health (Heart, Lung, and Blood Institute)-funded Wisconsin ...
7 hours ago | not rated yet | 0 |
In their quest to learn more about the variability of cells between and within tissues, biomedical scientists have devised tools capable of simultaneously measuring dozens of characteristics of individual ...
8 hours ago | 5 / 5 (2) | 0 |
A new study looking at sleep-disordered breathing (SDB) and markers for Alzheimer's disease (AD) risk in cerebrospinal fluid (CSF) and neuroimaging adds to the growing body of research linking the two.
7 hours ago | 5 / 5 (1) | 0 |
Scientists at Johns Hopkins have turned their view of osteoarthritis (OA) inside out. Literally. Instead of seeing the painful degenerative disease as a problem primarily of the cartilage that cushions joints, ...
8 hours ago | 5 / 5 (3) | 0 |
The hunt for an HIV vaccine has gobbled up $8 billion in the past decade, and the failure of the most recent efficacy trial has delivered yet another setback to 26 years of efforts.
12 hours ago | not rated yet | 0
Gourmands and foodies everywhere have long recognized ginger as a great way to add a little peppery zing to both sweet and savory dishes; now, a study from researchers at Columbia University shows purified components of the ...
7 hours ago | not rated yet | 0